GWAS meta-analyses clarify the genetics of cervical phenotypes and inform risk stratification for cervical cancer.


Journal

Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958

Informations de publication

Date de publication:
05 06 2023
Historique:
received: 21 11 2022
revised: 22 02 2023
accepted: 06 03 2023
medline: 8 6 2023
pubmed: 18 3 2023
entrez: 17 3 2023
Statut: ppublish

Résumé

Genome-wide association studies (GWAS) have successfully identified associations for cervical cancer, but the underlying mechanisms of cervical biology and pathology remain uncharacterised. Our GWAS meta-analyses fill this gap, as we characterise the genetic architecture of cervical phenotypes, including cervical ectropion, cervicitis, cervical dysplasia, as well as up to 9229 cases and 490 304 controls for cervical cancer from diverse ancestries. Leveraging the latest computational methods and gene expression data, we refine the association signals for cervical cancer and propose potential causal variants and genes at each locus. We prioritise PAX8/PAX8-AS1, LINC00339, CDC42, CLPTM1L, HLA-DRB1 and GSDMB as the most likely candidate genes for cervical cancer signals, providing insights into cervical cancer pathogenesis and supporting the involvement of reproductive tract development, immune response and cellular proliferation/apoptosis. We construct a genetic risk score (GRS) that is associated with cervical cancer [hazard ratios (HR) = 3.1 (1.7-5.6) for the top 15% vs lowest 15% of individuals], and with other HPV- and immune-system-related diagnoses in a phenome-wide association study analysis. Our results propose valuable leads for further functional studies and present a GRS for cervical cancer that allows additional risk stratification and could potentially be used to personalise the conventional screening strategies for groups more susceptible to cervical cancer.

Identifiants

pubmed: 36929174
pii: 7078905
doi: 10.1093/hmg/ddad043
pmc: PMC10244231
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2103-2116

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press.

Références

Clin Infect Dis. 2007 Apr 1;44 Suppl 3:S102-10
pubmed: 17342663
Nat Genet. 2013 Aug;45(8):918-22
pubmed: 23817570
Expert Rev Vaccines. 2014 Aug;13(8):931-4
pubmed: 24935354
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
J Allergy Clin Immunol. 2018 Nov;142(5):1469-1478.e2
pubmed: 29330013
Dermatol Ther. 2010 Sep-Oct;23(5):523-32
pubmed: 20868406
Int J Epidemiol. 2015 Aug;44(4):1137-47
pubmed: 24518929
PLoS Comput Biol. 2015 Apr 17;11(4):e1004219
pubmed: 25885710
Biomed Pharmacother. 2019 Dec;120:109423
pubmed: 31550677
PLoS One. 2014 Mar 27;9(3):e90099
pubmed: 24675552
Int J Oncol. 2015 Feb;46(2):757-63
pubmed: 25394485
Int J Cancer. 2017 May 1;140(9):1998-2002
pubmed: 28124469
Int J Cancer. 2002 May 10;99(2):260-6
pubmed: 11979442
Papillomavirus Res. 2019 Jun;7:132-134
pubmed: 30954690
Nat Genet. 2015 Nov;47(11):1236-41
pubmed: 26414676
J Cell Biochem. 2019 May;120(5):8272-8279
pubmed: 30485513
Hum Mol Genet. 2016 Nov 15;25(22):5046-5058
pubmed: 28171565
Cancer Res. 2021 Feb 15;81(4):806-810
pubmed: 33361393
J Pers Med. 2015 Apr 16;5(2):96-106
pubmed: 25894366
Nat Genet. 2021 Sep;53(9):1290-1299
pubmed: 34493866
JAMA. 2017 Oct 10;318(14):1377-1384
pubmed: 29049590
Ann Rheum Dis. 2015 Jul;74(7):1360-7
pubmed: 24618265
Science. 2020 Sep 11;369(6509):1318-1330
pubmed: 32913098
Cancer Epidemiol. 2020 Aug;67:101748
pubmed: 32562888
Nat Genet. 2018 Sep;50(9):1335-1341
pubmed: 30104761
PLoS One. 2017 Jan 20;12(1):e0167742
pubmed: 28107422
Science. 2020 May 29;368(6494):
pubmed: 32299851
Int J Cancer. 2005 Nov 10;117(3):510-4
pubmed: 15906352
Transl Oncol. 2008 Jul;1(2):73-83
pubmed: 18633457
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Hum Mol Genet. 2017 May 1;26(9):1612-1621
pubmed: 28334846
Nat Genet. 2010 Oct;42(10):874-9
pubmed: 20852632
Nature. 2015 Feb 19;518(7539):317-30
pubmed: 25693563
J Infect Dis. 2002 Dec 1;186(11):1565-74
pubmed: 12447731
Nat Commun. 2021 Feb 3;12(1):764
pubmed: 33536417
Genome Res. 2012 Sep;22(9):1790-7
pubmed: 22955989
PLoS One. 2020 Jun 18;15(6):e0234813
pubmed: 32555638
Nat Commun. 2017 Nov 28;8(1):1826
pubmed: 29184056
Hum Genet. 2021 Sep;140(9):1353-1365
pubmed: 34268601
Hum Mol Genet. 2017 Sep 15;26(18):3639-3650
pubmed: 28911207
Am J Hum Genet. 2002 Sep;71(3):543-53
pubmed: 12145745
Am J Hum Genet. 2018 May 3;102(5):776-793
pubmed: 29706346
Nat Genet. 2020 Jul;52(7):669-679
pubmed: 32514122
Nat Commun. 2021 Feb 12;12(1):970
pubmed: 33579919
PLoS One. 2013 Jun 06;8(6):e64683
pubmed: 23762245
Onco Targets Ther. 2020 Nov 16;13:11711-11724
pubmed: 33235461
BMC Bioinformatics. 2010 May 28;11:288
pubmed: 20509871
Bioinformatics. 2017 Jan 15;33(2):272-279
pubmed: 27663502
Int J Cancer. 2000 Dec 1;88(5):698-701
pubmed: 11072236
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Lancet Oncol. 2021 Apr;22(4):548-557
pubmed: 33794208
Nat Commun. 2020 Sep 4;11(1):4423
pubmed: 32887889
Biomed Pharmacother. 2019 Dec;120:109444
pubmed: 31562978
Am J Hum Genet. 2015 Oct 1;97(4):576-92
pubmed: 26430803
Nat Genet. 2016 Nov;48(11):1443-1448
pubmed: 27694958
Nat Genet. 2018 Feb;50(2):229-237
pubmed: 29292387
J Natl Cancer Inst. 2013 May 1;105(9):624-33
pubmed: 23482656
Mayo Clin Proc. 2011 Feb;86(2):147-50; quiz 151
pubmed: 21270291
Eur J Hum Genet. 2017 Jun;25(7):869-876
pubmed: 28401899
Front Oncol. 2014 Jun 19;4:119
pubmed: 24995157
Nat Med. 2021 Nov;27(11):1876-1884
pubmed: 34782789
PLoS Genet. 2017 Aug 14;13(8):e1006866
pubmed: 28806749

Auteurs

Mariann Koel (M)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu 51010, Estonia.

Urmo Võsa (U)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu 51010, Estonia.

Maarja Jõeloo (M)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu 51010, Estonia.

Kristi Läll (K)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu 51010, Estonia.

Natàlia P Gualdo (NP)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu 51010, Estonia.

Hannele Laivuori (H)

Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki 00014, Finland.
Faculty of Medicine and Health Technology, Department of Obstetrics and Gynecology, Tampere University Hospital and Tampere University, Tampere 33520, Finland.
Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki 00014, Finland.

Susanna Lemmelä (S)

Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki 00014, Finland.

Mark Daly (M)

Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki 00014, Finland.

Priit Palta (P)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu 51010, Estonia.
Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki 00014, Finland.

Reedik Mägi (R)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu 51010, Estonia.

Triin Laisk (T)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu 51010, Estonia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH